The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.

doi:10.1128/AAC.00714-15

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.

Antimicrobial agents and chemotherapy - 1 Jul 2015

Sánchez María Blanca, Martínez José Luis

Abstract excerpt

Trimethoprim-sulfamethoxazole (co-trimoxazole) is one of the antimicrobials of choice for the treatment of Stenotrophomonas maltophilia infections. The analysis of mutants either lacking or overexpressing the efflux pump SmeDEF shows that this efflux pump contributes to intrinsic and acquired co-trimoxazole resistance in S. maltophilia. Since SmeDEF can extrude a variety of antibiotics, selection with such...

Topics

Anti-Bacterial Agents
Bacterial Proteins
Drug Resistance, Bacterial
Membrane Transport Proteins
Microbial Sensitivity Tests
Mutation
Quinolones
Stenotrophomonas maltophilia
Trimethoprim, Sulfamethoxazole Drug Combination

Source

Open in PubMed Open full text

Identifiers

PMID: 25918144
DOI: 10.1128/AAC.00714-15
PMCID: PMC4468665

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics